- Home
- KPTI vs ORGN Comparison
KPTI vs ORGN Comparison
Compare KPTI & ORGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- ORGN
- Stock Information
- Founded
- KPTI 2008
- ORGN 2008
- Country
- KPTI United States
- ORGN United States
- Employees
- KPTI N/A
- ORGN N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- ORGN Major Chemicals
- Sector
- KPTI Health Care
- ORGN Industrials
- Exchange
- KPTI Nasdaq
- ORGN Nasdaq
- Market Cap
- KPTI 121.2M
- ORGN 124.1M
- IPO Year
- KPTI 2013
- ORGN N/A
- Fundamental
- Price
- KPTI $0.89
- ORGN $1.48
- Analyst Decision
- KPTI Strong Buy
- ORGN Strong Buy
- Analyst Count
- KPTI 4
- ORGN 1
- Target Price
- KPTI $5.00
- ORGN $3.00
- AVG Volume (30 Days)
- KPTI 864.9K
- ORGN 1.3M
- Earning Date
- KPTI 10-31-2024
- ORGN 11-07-2024
- Dividend Yield
- KPTI N/A
- ORGN N/A
- EPS Growth
- KPTI N/A
- ORGN N/A
- EPS
- KPTI N/A
- ORGN N/A
- Revenue
- KPTI $145,668,000.00
- ORGN $34,061,000.00
- Revenue This Year
- KPTI $6.41
- ORGN $10.62
- Revenue Next Year
- KPTI $11.85
- ORGN $175.99
- P/E Ratio
- KPTI N/A
- ORGN N/A
- Revenue Growth
- KPTI N/A
- ORGN 295.97
- 52 Week Low
- KPTI $0.62
- ORGN $0.44
- 52 Week High
- KPTI $1.95
- ORGN $1.90
- Technical
- Relative Strength Index (RSI)
- KPTI 62.92
- ORGN 49.11
- Support Level
- KPTI $0.71
- ORGN $1.50
- Resistance Level
- KPTI $0.94
- ORGN $1.69
- Average True Range (ATR)
- KPTI 0.07
- ORGN 0.13
- MACD
- KPTI 0.02
- ORGN -0.04
- Stochastic Oscillator
- KPTI 78.86
- ORGN 14.29
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others.